Lupron
(leuprolide acetate)Phase 3Small molecule
Leuprolide acetate is used to treat advanced prostate cancer by lowering testosterone levels, and it's also used to treat endometriosis and uterine fibroids in women by temporarily stopping the release of certain hormones.[1] Lupron is currently being investigated across 15 indications[3], with its most advanced program in Phase 3.[1]
Lupron is one of 223 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.
15
Indications
113
Total Trials
19
Active Trials
222
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 15 indications
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Lupron
EEastern Cooperative Oncology Group
Phase 3
Nizoral
WWim Janssens
Phase 3
Triptorelin Embonate
IpsenPhase 3
Androgen Deprivation Treatment
MMedical University of Vienna
Phase 3
Lupron Depot
RRepros Therapeutics Inc.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer53 trials
Management of Castration-Resistant Prostate Cancer with Oligometastases
Active, not recruiting·SSir Mortimer B. Davis - Jewish General Hospital·Phase 2/3·NCT02685397·102 enrolled
Show 50 more trials
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
Completed·—·Phase 2·NCT02770391·54 enrolled
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03043807·26 enrolled
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Recruiting·—·Phase 2·NCT04734730·70 enrolled
A Study of Definitive Therapy to Treat Prostate Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02716974·26 enrolled
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Withdrawn·—·Phase 2·NCT00003517
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
Terminated·—·Phase 2·NCT03093272·9 enrolled
Metastatic Prostate Cancer7 trials
Show 4 more trials
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Active, not recruiting·—·Phase 2·NCT03361735·25 enrolled
Breast Cancer5 trials
Show 2 more trials
Central precocious puberty3 trials
Prostate Adenocarcinoma3 trials
39 more indications
Androgen Deprivation Therapy2 trials
Radiotherapy2 trials
Alzheimer's Disease2 trials
Postpartum Depression1 trial
Lupron1 trial
Lupron Sex Offender Therapy
Unknown status·—·Phase 2/3·NCT00220350·10 enrolled
Outcome1 trial
The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes
Unknown status·ZZekai Tahir Burak Women's Health Research and Education Hospital·N/A·NCT02114645·100 enrolled
Cognition1 trial
Randomized1 trial
Testosterone1 trial
Leiomyoma1 trial
High Risk1 trial
Post-operative or Early Salvage XRT and ADT for High Risk PCa
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00949962·87 enrolled
Menopausal Women1 trial
Hematopoietic Stem Cell Transplantation1 trial
Uterine leiomyoma1 trial
Acanthosis Nigricans1 trial
Prostate1 trial
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Completed·—·Phase 2·NCT02268175·75 enrolled
Cystic1 trial
Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection
Unknown status·—·Phase 4·NCT04094467·150 enrolled
Polycystic Ovarian Syndrome (PCOS)1 trial
PSA1 trial
Castration-Resistant Prostate Carcinoma1 trial
Locally Advanced Salivary Gland Carcinoma1 trial
Prostate Carcinoma1 trial
Hypogonadotropic Hypogonadism1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for leuprolide acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details